Paraneoplastic polyarteritis nodosa with cerebral masses: case report and literature review

Veitch, David; Tsai, Ted; Watson, Shaun; Joshua, Fredrick

doi:10.1111/1756-185x.12377

Cited by 7 publications

(2 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, there is no difference between patients treated with combination therapy versus monotherapy. Therefore, vasculitis can be associated with ICI therapy but at the same time they can be a paraneoplastic manifestation of many cancers, first of all melanoma [60,61]. In particular, temporal arteritis was over-reported for patients with melanoma treated with ipilimumab.…”

Section: Vasculitismentioning

confidence: 99%

Cardiovascular Toxicity of Immune Checkpoint Inhibitors: Clinical Risk Factors

et al. 2021

View full text Add to dashboard Cite

Section: Vasculitismentioning

confidence: 99%

Cardiovascular Toxicity of Immune Checkpoint Inhibitors: Clinical Risk Factors

et al. 2021

View full text Add to dashboard Cite

“…Like other vasculitides, PAN can be induced by the use of certain drugs, such as minocycline [41]. The association between PAN and neoplasia is well established, especially for hematological malignancies, such as hairy T cell leukemia, or, more recently, myelodysplastic syndrome (MDS) [42][43][44][45][46]. In a study by Roupie et al, out of 70 patients with MDS and vasculitis, 9% presented with PAN.…”

Section: Physiopathologymentioning

confidence: 99%

Polyarteritis Nodosa: Old Disease, New Etiologies

Wolff,

Horisberger,

Moi

et al. 2023

IJMS

View full text Add to dashboard Cite

Polyarteritis nodosa (PAN), also known as panarteritis nodosa, represents a form of necrotizing vasculitis that predominantly affects medium-sized vessels, although it is not restricted to them and can also involve smaller vessels. The clinical presentation is heterogeneous and characterized by a significant number of patients exhibiting general symptoms, including asthenia, fever, and unintended weight loss. Although PAN can involve virtually any organ, it preferentially affects the skin, nervous system, and the gastrointestinal tract. Orchitis is a rare but specific manifestation of PAN. The absence of granulomas, glomerulonephritis, and anti-neutrophil cytoplasmic antibodies serves to distinguish PAN from other types of vasculitis. Major complications consist of hemorrhagic and thrombotic events occurring in mesenteric, cardiac, cerebral, and renal systems. Historically, PAN was frequently linked to hepatitis B virus (HBV) infection, but this association has dramatically changed in recent years due to declining HBV prevalence. Current epidemiological research often identifies a connection between PAN and genetic syndromes as well as neoplasia. This article provides a comprehensive review of PAN, specifically focusing on the progression of its clinical manifestations over time.

show abstract

Vasculitis associated with immune checkpoint inhibitors—a systematic review

2018

View full text Add to dashboard Cite

Recent experimental and genetic studies have implicated the role of programmed cell death protein 1 (PD-1), programmed cell death protein-ligand 1 (PDL-1), and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) in the pathogenesis of medium and large vessel vasculitis. This study sought to evaluate the occurrence and nature of vasculitis associated with cancer treatment using immune checkpoint inhibition (anti-PD-1, anti-PDL-1, and anti-CTLA4). A systematic review of the medical literature was conducted by searching all available clinical data up to February 2018 in several databases and search engines including Cochrane Library, Embase, Google Scholar, Medline, Scopus, Web of Science, and Clinicaltrials.gov . Searches included the following FDA-approved anti-PD1 (nivolumab and pembrolizumab), anti-PDL1 (atezolizumab, avelumab, and durvalumab), and anti-CTLA4 (ipilimumab). The vasculitis cases were compiled and classified based on the 2012 revised Chapel Hill Consensus Conference nomenclature. The clinical feature of the vasculitis cases and their relationship to immune checkpoint inhibition was assessed. There were 53 cases of vasculitis of which 20 were confirmed. The main reported type of vasculitis was large vessel vasculitis and vasculitis of the central and peripheral nervous system. All cases resolved with either holding the immune checkpoint inhibitors and/or administering glucocorticoids. No death related to vasculitis was reported. Vasculitis, namely large vessel and vasculitis of the nervous system, is associated with immune checkpoint inhibition. Results of this study add to the growing evidence regarding the relationship between immune checkpoints and vasculitis and suggest that the pathway may be a therapeutic target.

show abstract

Paraneoplastic polyarteritis nodosa with cerebral masses: case report and literature review

Cited by 7 publications

References 15 publications

Cardiovascular Toxicity of Immune Checkpoint Inhibitors: Clinical Risk Factors

Cardiovascular Toxicity of Immune Checkpoint Inhibitors: Clinical Risk Factors

Polyarteritis Nodosa: Old Disease, New Etiologies

Vasculitis associated with immune checkpoint inhibitors—a systematic review

Contact Info

Product

Resources

About